Skip to main content
    Novo Nordisk logo

    Novo Nordisk

    Health care

    TickerNOVO-B.COISINDK0062498333

    Novo Nordisk stock analysis: how the business works, what moves it and what to check

    How Novo Nordisk makes money, what moves the stock, which figures to check and the risks to keep in view.

    Peakwise Research · · Updated · 4 min read

    Contents

    Novo Nordisk created the modern market for weight-loss drugs with Wegovy and Ozempic. After a huge rally, the stock fell hard when growth slowed and Eli Lilly gained ground. The question now is how much of the obesity market Novo can keep.

    CompanyNovo Nordisk A/S
    TickerNOVO-B.CO / NVO
    ListingNasdaq Copenhagen and NYSE
    SectorHealth Care
    ISINDK0062498333
    HeadquartersBagsværd, Denmark

    Novo Nordisk at a glance

    • Leader in diabetes and obesity medicines: Ozempic and Wegovy.
    • Competition from Eli Lilly has intensified.
    • Controlled by the Novo Nordisk Foundation.

    A short history

    Novo Nordisk was formed in 1989 by the merger of two Danish insulin makers, Novo and Nordisk, both founded in the 1920s. Its GLP-1 medicines Ozempic (2017) and Wegovy (2021) made it Europe's most valuable company for a time. Growth slowed in 2025, and leadership changed.

    How Novo Nordisk makes money

    Diabetes and Obesity care is the dominant segment, with semaglutide sold as Ozempic, Rybelsus and Wegovy plus insulins. Rare disease treats haemophilia and growth disorders. Most sales come from the US.

    Competitive position

    Novo has decades of experience in diabetes and large manufacturing capacity. The Novo Holdings parent bought Catalent to expand production. Eli Lilly is the main competitor, with many new entrants following.

    What moves Novo Nordisk stock

    • Wegovy and Ozempic sales. Growth rate and US pricing.
    • Competition from Lilly. Zepbound and Mounjaro compete directly.
    • Next-generation drugs. CagriSema and oral semaglutide.
    • Compounded copies. Cheaper compounded versions affected US demand.

    Novo Nordisk key figures, up to date

    NOVO-B.CO

    The AI stock analysis computes these figures from current market data, with a short comment on each number and the method behind the fair value range.

    Free for 7 days. Not investment advice.

    The numbers worth checking

    Not every ratio matters equally for every company. For Novo Nordisk, these are the figures that tell you the most. If a term is new, the guides on the P/E ratio and fair value explain the basics.

    • Sales growth at constant exchange rates. Novo reports this as the main figure.
    • Operating profit growth. Guidance updates move the stock.
    • Market share in obesity prescriptions. Weekly US prescription data.
    • Capital spending. Including the Catalent site acquisitions.

    The best source for these figures is the latest annual or quarterly report on the Novo Nordisk investor relations site. Our guide on how to read an earnings report shows where to find them.

    How to think about valuation

    Novo is valued on P/E and expected growth. Investors compare it with Eli Lilly and model the obesity market.

    Opportunities

    • Oral Wegovy. Pill versions widen the market.
    • New indications. Heart, kidney and liver diseases.
    • Next-generation drugs. CagriSema and others.

    Risks to keep in view

    • Competition. Lilly and new entrants.
    • Pricing pressure. US price negotiations and political pressure.
    • Pipeline setbacks. Trial results below expectations hit the stock.

    A useful exercise is to write the bull case and the bear case for Novo Nordisk in three sentences each. If you cannot fill the bear case, you have not looked hard enough. How to write an investment thesis walks through it.

    What to watch in the next report

    • Wegovy and Ozempic sales
    • US prescription trends
    • Pipeline readouts

    How to research Novo Nordisk stock with Peakwise

    The quickest way to put the points above against current figures is the AI stock analysis: search for Novo Nordisk, generate the report and check the executive summary, the financials and the fair value range. The report states the method behind its estimate, so you can see which assumptions drive it.

    For anything the report leaves open, ask the investment chatbot. It runs a web search for each question and links the sources it used, so you can open them and check. A good first question:

    How did Novo Nordisk's sales guidance change this year and what were the reasons?

    To look at the chart itself, the AI chart analysis describes trend, support and resistance levels and patterns over one month, one year and the full history.

    This article describes the business and the questions worth asking. It contains no price targets and no forecasts, and it is not investment advice. Check current figures before you make a decision.

    Frequently asked questions

    Both contain semaglutide. Ozempic is approved for type 2 diabetes, Wegovy at a higher dose for weight management.

    That depends on your goals, your time horizon and the price you pay, so no article can answer it for you. For Novo Nordisk, the points that carry the most weight are Wegovy and Ozempic sales, competition from Lilly and, on the risk side, competition. Check them with current figures and decide for yourself. This is not investment advice.

    Competition. Lilly and new entrants. Pricing pressure. US price negotiations and political pressure. Pipeline setbacks. Trial results below expectations hit the stock.

    Novo Nordisk A/S trades under the ticker NOVO-B. The ISIN is DK0062498333. Listing: Nasdaq Copenhagen and NYSE.

    Check Novo Nordisk yourselfin one report

    The AI stock analysis puts financials, news, analyst consensus, a fair value range with its method, and risks and opportunities in one report.

    Free for 7 days. Not investment advice.